Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.

Cordido F, Peñalva A, Peino R, Casanueva FF, Dieguez C

Metabolism: clinical and experimental1 Jun 1995Cited by 16 (Europe PMC)

PMID7783658DOI10.1016/0026-0495(95)90187-6PepBankPUB-07783658

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In normal subjects, GHRH plus GHRP‑6 increased plasma GH to a peak of 76.7 micrograms/L at 30 minutes.
In plain wordsIn normal subjects, GHRH plus GHRP‑6 increased growth hormone, with a peak at 30 minutes.
Peptide
GHRP-6
Outcome
IncreaseGH peak in normal subjects
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH peak
76.7 micrograms/L
GHRH plus GHRP-6 in normal subjects
Source sentences
Summary
In normal subjects, administration of GHRH plus GHRP-6 induced a marked increase in plasma GH with a peak at 30 minutes (mean +/- SEM, 76.7 +/- 9.7 micrograms/L), which was similar to that obtained after pretreatment with pyridostigmine (74.7 +/- 9.4 micrograms/L).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0778365801
02HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In normal subjects, pyridostigmine pretreatment did not alter the GH peak after GHRH plus GHRP‑6.
In plain wordsIn normal subjects, pyridostigmine did not change the growth hormone peak compared with GHRH plus GHRP‑6 alone.
Peptide
GHRP-6
Outcome
No significant changePyridostigmine effect on GH peak in normal subjects
Study
n: not reported in source
Comparator
GHRH plus GHRP-6 without pyridostigmine
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH peak
76.7 micrograms/L
GHRH plus GHRP-6 without pyridostigmine, normal subjects
GH peak
74.7 micrograms/L
pyridostigmine plus GHRH plus GHRP-6, normal subjects
Source sentences
Summary
In normal subjects, administration of GHRH plus GHRP-6 induced a marked increase in plasma GH with a peak at 30 minutes (mean +/- SEM, 76.7 +/- 9.7 micrograms/L), which was similar to that obtained after pretreatment with pyridostigmine (74.7 +/- 9.4 micrograms/L).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0778365802
03HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In obese patients, GHRH plus GHRP‑6 increased GH secretion to a peak of 42.2 micrograms/L at 15 minutes.
In plain wordsIn obese patients, GHRH plus GHRP‑6 increased growth hormone, with a peak at 15 minutes.
Peptide
GHRP-6
Outcome
IncreaseGH peak in obese patients
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH peak
42.2 micrograms/L
GHRH plus GHRP-6 in obese patients
Source sentences
Summary
In obese patients, combined administration of GHRH plus GHRP-6 induced a clear increase in GH secretion with a peak at 15 minutes of 42.2 +/- 10.0 micrograms/L, which was also unaffected after pretreatment with pyridostigmine (38.4 +/- 5.8 micrograms/L).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0778365803
04HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In obese patients, pyridostigmine pretreatment did not alter the GH peak after GHRH plus GHRP‑6.
In plain wordsIn obese patients, pyridostigmine did not change the growth hormone peak compared with GHRH plus GHRP‑6 alone.
Peptide
GHRP-6
Outcome
No significant changePyridostigmine effect on GH peak in obese patients
Study
n: not reported in source
Comparator
GHRH plus GHRP-6 without pyridostigmine
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH peak
42.2 micrograms/L
GHRH plus GHRP-6 without pyridostigmine, obese patients
GH peak
38.4 micrograms/L
pyridostigmine plus GHRH plus GHRP-6, obese patients
Source sentences
Summary
In obese patients, combined administration of GHRH plus GHRP-6 induced a clear increase in GH secretion with a peak at 15 minutes of 42.2 +/- 10.0 micrograms/L, which was also unaffected after pretreatment with pyridostigmine (38.4 +/- 5.8 micrograms/L).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0778365804
05HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
GH response after GHRH plus GHRP‑6 was lower in obese patients than in normal controls.
In plain wordsObese patients had a lower growth hormone response to GHRH plus GHRP‑6 than normal controls.
Peptide
GHRP-6
Outcome
DecreaseGH AUC after dual combination
Study
n: not reported in source
Comparator
Normal controls given GHRH plus GHRP-6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
1846 not stated
Obese patients after GHRH plus GHRP-6
GH AUC
4773 not stated
Controls after GHRH plus GHRP-6
Source sentences
Summary
The GH response was lower in obese patients than in controls as assessed by the area under the curve after administration of both GHRH plus GHRP-6 (1,846 +/- 396 v 4,773 +/- 653, P < .01)
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0778365805
06HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
GH response after pyridostigmine plus GHRH plus GHRP‑6 was lower in obese patients than in normal controls.
In plain wordsObese patients had a lower growth hormone response to pyridostigmine plus GHRH plus GHRP‑6 than normal controls.
Peptide
GHRP-6
Outcome
DecreaseGH AUC after triple combination
Study
n: not reported in source
Comparator
Normal controls given pyridostigmine plus GHRH plus GHRP-6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
1989 not stated
Obese patients after pyridostigmine plus GHRH plus GHRP-6
GH AUC
5098 not stated
Controls after pyridostigmine plus GHRH plus GHRP-6
Source sentences
Summary
The GH response was lower in obese patients than in controls as assessed by the area under the curve after administration of both GHRH plus GHRP-6 (1,846 +/- 396 v 4,773 +/- 653, P < .01) and pyridostigmine plus GHRH plus GHRP-6 (1,989 +/- 372 v 5,098 +/- 679, P < .005).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0778365806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.